Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Dirloctocogene samoparvovec by Spark Therapeutics for Hemophilia A (Factor VIII Deficiency): Likelihood of Approval
Dirloctocogene samoparvovec is under clinical development by Spark Therapeutics and currently in Phase III for Hemophilia A (Factor VIII Deficiency)....